Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The SCID-hu myeloma model.

Joshua Epstein1, Shmuel Yaccoby

  • 1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Science, Little Rock, AK, USA.

Methods in Molecular Medicine
|June 22, 2005
PubMed
Summary

The severe combined immune deficient human (SCID-hu) myeloma model allows primary human myeloma cells to grow in a human bone marrow environment. This model is crucial for studying myeloma biology and therapy in vivo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice.

Haematologica·2025
Same author

EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression.

Cancers·2023
Same author

Growth and dormancy control of myeloma cells by mesenchymal stem cells.

Leukemia research·2023
Same author

Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers.

Genome research·2021
Same author

PHF19 inhibition as a therapeutic target in multiple myeloma.

Current research in translational medicine·2021
Same author

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).

Blood cancer journal·2020

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • The severe combined immune deficient human (SCID-hu) myeloma model is unique for in vivo growth of primary myeloma cells.
  • It utilizes a human bone marrow microenvironment within a SCID mouse host.

Purpose of the Study:

  • To detail the establishment and evaluation of the SCID-hu myeloma model.
  • To provide a platform for investigating human myeloma biology and therapy.

Main Methods:

  • Implantation of human fetal bone into SCID mice.
  • Direct injection of primary myeloma cells into the implanted bone.
  • Monitoring of myeloma manifestations in the SCID host.

Main Results:

  • Successful engraftment and growth of human myeloma cells in the human bone marrow microenvironment.
  • Induction of characteristic myeloma signs, including M protein in serum and osteolysis.
  • Demonstration of the model's utility for in vivo research.

Conclusions:

  • The SCID-hu model is the sole platform for studying human myeloma in a human microenvironment.
  • This model is essential for advancing the understanding and treatment of multiple myeloma.

Related Experiment Videos